Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Medicus said it submitted an optimized seamless Phase 2b/3 registration-intent protocol to the FDA for Teverelix in advanced prostate cancer. The design starts with about 80 randomized patients and expands to about 608 if continuation criteria are met, targeting a registrational pathway in patients at increased cardiov
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategyPHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. NASDAQ:MDCX (“Medicus” or the “Com…
Medicus Pharma (MDCX) submitted an optimized Teverelix® registrational protocol to the FDA to create a partner-ready program in advanced prostate cancer.